Select area of interest here

imageimageimagefacebooklinkedintwitter
Font SizeA-AA+

5th European Phenylketonuria Group Symposium 'Advances and Challenges in PKU'

  • Location:Istanbul, Turkey
  • Date:15 March 2013 - 16 March 2013
 

5th European Phenylketonuria Group (EPG) Symposium “Advances and Challenges in PKU

Aims of the symposium

Phenylketonuria (PKU) is an active field of investigation, and new diagnostic and treatment options are emerging that may reduce the burden of a life-long and limiting dietary management for these patients, their families and the society.
Basic and clinical research is today focusing on brain metabolism in PKU patients and its repercussion on neurological functions, on a better clinical characterization by biochemical and genetic analysis, and also on developing new therapeutic strategies or implementing the use of those already available, such as diet and sapropterin dihydrochloride,
Furthermore, evidence-based international guidelines are being developed to provide standardization in PKU management, including appropriate biomolecular diagnosis, treatment’s choice, evaluation of response to therapy, and achievement of targeted blood phenylalanine levels, also considering the social and economical impact of this disease.
The European Phenylketonuria Group (EPG) together with Serono Symposia International Foundation (SSIF) consider essential to continue their series of successful meetings on PKU, and are organizing the 2013 annual symposium dedicated to that. Aims of this meeting are to review the most important achievements of research in the field of PKU and to provide participants with solutions for optimizing patient management in their daily clinical practice.

Learning objectives

After attending the symposium, participants will better understand the importance of and will be able to improve their clinical practice on the following aspects of PKU:

  • Brain pathology in PKU
  • New chemical chaperons for PKU
  • Genetic modifiers and PKU
  • Management of BH4 deficiencies
  • Assessment of executive function in PKU
  • Neuropsychological assessment in PKU
  • Enzyme substitution therapy for PKU
  • Development of EU guidelines for PKU management
  • Metabolomics in PKU

Target audience

Specialists in pediatric and adult inherited metabolic disorders, dietitians, nutritionists, clinical biochemists and genetists, basic scientists, psychologists, nurses and all health care professionals dealing with PKU.

Learning Effectiveness Project

Serono Symposia International Foundation is conducting a Learning Effectiveness Project at meetings during 2013. The meeting ' 5th European Phenylketonuria Group Symposium 'Advances and Challenges in PKU' has been chosen to participate in this project.

Find out more about the Learning Effectiveness Project

Accreditation

Serono  Symposia  International  Foundation  (www.seronosymposia.org) is  accredited  by  the  European  Accreditation  Council  for Continuing  Medical  Education  (EACCME ® )  to  provide  the  following  CME  activity  for  medical  specialists.  The  EACCME ® is  an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The conference 5 th European Phenylketonuria Group (EPG) Symposium “Advances and Challenges in PKU” (15-16 March 2013 -Istanbul, Turkey) is designated for a maximum of 9 (nine) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME ® credits are recognized by the American

Medical Association (AMA) towards the Physician's Recognition Award (PRA). To convert EACCME ® credit to AMA PRA category 1 credit, please contact the AMA.

 

You are about to leave this website. The content of the site you are about
to visit is not controlled by EXCEMED.

Do you really want to leave?